From the Journals

Excellent prognosis for cystic RCC evaluated with radiologic threshold of greater than 50%


 

FROM THE JOURNAL OF UROLOGY

Studies evaluating radiologic criteria for cRCC diagnosis have suggested that cystic changes in 5%-45% of the total mass observed on imaging are associated with favorable survival. Thus, the authors sought to improve the preoperative assessment of cystic renal masses by evaluating cRCC as an enhancing renal lesion that is greater than 50% cystic on cross-sectional imaging. The goal of the current study was then to compare the long-term outcomes of patients with cRCC who underwent surgery and active surveillance using this hypothesized threshold.

The cohort included 138 patients who underwent surgery at Memorial Sloan Kettering Cancer Center for a renal mass from January 2000 to December 2015, and of this group, 102 (73.9%) had renal cell carcinoma and 36 (26.1%) had benign masses. Most of the tumors were Fuhrman grade 1-2 (77.5%), ≤pT2 stage (83.4%) and clear cell histology (65.9%), while the majority of cRCC lesions were Bosniak 3 and 4 (93.5%) and had a solid component of less than 25% (83.3%). On multivariate analysis, men (P = .007) were more likely to have malignant lesions and Bosniak 3 lesions were more likely to be malignant (P = .01).

In the subgroup of 38 active surveillance patients, 27 (71.1%) remained on active surveillance while 11 (28.9%) subsequently had surgery, of which all underwent partial nephrectomy. The median overall growth rate for lesions was 1.0 mm/year (IQR 0-2.8) over 25.3 months (IQR 16.3-44.8), and no evidence of recurrence or metastasis was reported in any of these patients at a median follow-up of 4.3 years (IQR 2.1-5.7) from first imaging diagnosis or 6.9 years (IQR 4.9-8.5) after surgery.

“We believe that our radiologic definition allows for more inclusive criteria of cRCC and would encourage kidney sparing approaches or implementation of AS protocols when feasible,” the authors concluded.

SOURCE: Hakimi A et al. J Urol. 2018 Feb 26 doi: 10.1016/j.juro.2018.02.3087

Pages

Recommended Reading

FDA approves cabozantinib for the frontline treatment of advanced RCC
MDedge Hematology and Oncology
Mutations linked to checkpoint inhibitor response in RCC
MDedge Hematology and Oncology
In Brazil, few patients get second- and third-line treatment for metastatic RCC
MDedge Hematology and Oncology
Phase 1 study: Human IL-10 plus checkpoint blockade looks promising in RCC, NSCLC
MDedge Hematology and Oncology
OS similar among mRCC patients enrolled in clinical trials across different geographic regions
MDedge Hematology and Oncology
Retroperitoneal lymphadenectomy did not impact OS and DFS for high risk, nonmetastatic renal cell carcinoma
MDedge Hematology and Oncology
Atezolizumab-bevacizumab combo tops sunitinib as first-line therapy for RCC
MDedge Hematology and Oncology
ERV expression may predict response to immune checkpoint blockade in ccRCC, other solid tumors
MDedge Hematology and Oncology
Axitinib/pembrolizumab combo safe, effective against mRCC
MDedge Hematology and Oncology
Immunotherapy regimen influences inflammatory arthritis presentation
MDedge Hematology and Oncology